Straits Times Index
3,330.77 -0.04 (-0.00%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,245.37 -39.97 (-0.48%) Bitcoin USD
69,293.41 -1,473.77 (-2.08%) CMC Crypto 200
1,440.61 -38.09 (-2.58%)
MRK Jul 2024 85.000 put
| Previous close | 0.1800 |
| Open | 0.0900 |
| Bid | 0.0400 |
| Ask | 0.3300 |
| Strike | 85.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0900 - 0.1800 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
Insider MonkeyThe City With the highest HIV/AIDS Rates in the US
We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US. HIV Incidence and Prevalence in the United States The government of the United States has set a goal to reduce the […]
Business WireMerck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RAHWAY, N.J., June 05, 2024--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
